Diseases of the liver related to metabolic syndrome have emerged as the most common and
undertreated hepatic ailments. The cause of nonalcoholic fatty liver disease is the aberrant
accumulation of lipid in hepatocytes, though the mechanisms whereby this leads to
hepatocyte dysfunction, death, and hepatic fibrosis are still unclear. Insulin‐sensitizing
thiazolidinediones have shown efficacy in treating nonalcoholic steatohepatitis (NASH), but
their widespread use is constrained by dose‐limiting side effects thought to be due to …